Amgen's Phase 3 DeLLphi-305 study demonstrated that IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca's durvalumab significantly improves overall survival, progression-free survival, and response rates compared to durvalumab alone in patients with extensive stage small cell lung cancer (ES-SCLC). This marks the first Phase 3 trial showing a bispecific T-cell engager therapy benefits first-line maintenance treatment in ES-SCLC, potentially changing the treatment landscape for this aggressive cancer. The safety profile was consistent with known effects, with no new safety concerns. Amgen plans to present detailed data at an upcoming medical congress and seek regulatory approvals.
Jim Cramer recommended buying Johnson & Johnson (JNJ) shares during a recent dip, citing upcoming data from the Psych Congress conference and strong sales growth. Despite a 2.33% drop in the session, JNJ has outperformed the market with a 53.76% gain...
Investment firm BMO Capital downgraded Amgen's stock from "Outperform" to "Market Perform" following a major clinical trial failure by Novartis for a similar cholesterol drug. Novartis' drug pelacarsen failed in a late-stage Phase III trial, casting ...
Novartis announced that its drug pelacarsen, designed to lower the harmful cholesterol Lp(a), failed to significantly reduce cardiovascular events in a late-stage trial. This setback raises doubts about the effectiveness of targeting Lp(a) to prevent...
Representative David J. Taylor of Ohio reported six stock trades, selling biotech and tech shares like Amgen and Microsoft, while buying utilities, semiconductors, and regional bank stocks such as American Electric Power, Broadcom, and Fifth Third Ba...
The iShares Biotechnology ETF (IBB) surged 26% over three months ending September 4, 2026, outperforming the S&P 500's 4% gain by 22 points. This rally is driven by big pharmaceutical companies acquiring mid- and small-cap biotech firms to offset rev...
